|
cannabinoid receptor antagonist
|
CHEBI_73413 |
|
|
CB1 receptor antagonist
|
CHEBI_73416 |
|
|
alkaptonuria
|
DOID_9270 |
|
|
amino acid metabolic disorder
|
DOID_9252 |
|
|
hyperlysinemia
|
DOID_9274 |
|
|
EC 1.15.1.1 (superoxide dismutase) inhibitor
|
CHEBI_134084 |
|
|
EC 1.15.* (oxidoreductase acting on superoxide as acceptor) inhibitor
|
CHEBI_76742 |
|
|
ornithine carbamoyltransferase deficiency
|
DOID_9271 |
|
|
urea cycle disorder
|
DOID_9267 |
|
|
hypoxia-inducible factor pathway activator
|
CHEBI_134083 |
|
|
cystinuria
|
DOID_9266 |
|
|
ureteral disease
|
DOID_1426 |
|
|
histidine metabolism disease
|
DOID_9265 |
|
|
maple syrup urine disease
|
DOID_9269 |
|
|
organic acidemia
|
DOID_0060159 |
|
|
glycine encephalopathy
|
DOID_9268 |
|
|
matrix metalloproteinase inhibitor
|
CHEBI_50664 |
|
|
EC 6.3.2.19 (ubiquitin--protein ligase) inhibitor
|
CHEBI_75968 |
|
|
phenylketonuria
|
DOID_9281 |
|
|
metabotropic glutamate receptor antagonist
|
CHEBI_63963 |
|
